Schizophrenia News and Research

Latest Schizophrenia News and Research

New findings from STELARA psoriasis clinical trial to be presented at 22nd World Congress of Dermatology

New findings to be presented from pooled analyses of the STELARA psoriasis clinical development program showed that the safety profile of STELARA and rates of adverse events remained consistent and stable over time in adults with moderate to severe plaque psoriasis receiving up to four years of treatment.

25 May 2011

Brain areas responsible for motor behavior might represent therapeutic targets for bipolar disorder

A new study by motor control and psychology researchers at Indiana University suggests that postural control problems may be a core feature of bipolar disorder, not just a random symptom, and can provide insights both into areas of the brain affected by the psychiatric disorder and new potential targets for treatment.

25 May 2011

Evotec, PsychoGenics partner to offer integrated CNS drug discovery solutions

PsychoGenics Inc. today announced that it has entered into a strategic alliance with Evotec AG to provide integrated CNS drug discovery solutions to pharmaceutical and biotech companies.

25 May 2011

Disaster-response planning raises challenges for mental health services, bioethicists say

Johns Hopkins University bioethicists say disaster-response planning has generally overlooked the special needs of people who suffer from pre-existing and serious mental conditions.

24 May 2011

Johns Hopkins bioethicists urge disaster preparedness for mentally impaired

Johns Hopkins bioethicists say disaster-response planning has generally overlooked the special needs of people who suffer from pre-existing and serious mental conditions. Survivors already diagnosed with schizophrenia, dementia, addictions and bipolar disorder are vulnerable long before a disaster strikes, they point out.

23 May 2011

Researchers uncover new details of unusual biological mechanism in brains of diverse species

Researchers at the University of California, San Diego School of Medicine have uncovered new details of an unusual biological mechanism in the brains of diverse species that not only helps regulate how their brains develop, but also how they function later in life. The discovery could lead to new biomarkers for specific neurological diseases in humans and, possibly, the development of drugs to cure them.

21 May 2011

Adjusting life goals can help family caregivers prevent depressive symptoms: Study

Caring for a family member with a mental illness can be a taxing experience marked by personal sacrifices and psychological problems.

21 May 2011

Generic drugs to rule the market in the near future: Experts

According to the latest estimates for global drug sales, generic drug makers are going to be in for bumper profits. The growth in generics is expected to depress overall ‘pharma’ sales growth, as lower-priced copies replace top-dollar brand names. In fact, global sales growth could be reduced by half over the next five years, say experts.

19 May 2011

New interactive website for patients with schizophrenia

Schizophrenia24x7.com is a new, interactive website featuring helpful resources, information and interactive tools for people affected by schizophrenia.

18 May 2011

Study: MMN might predict risk of developing schizophrenia

There is a significant need for objective tests that could improve clinical prediction of future psychosis. One strategy has been to determine whether physiologic measures that are abnormal in people diagnosed with schizophrenia might also be useful in estimating the risk for developing this illness. This is the strategy taken by German and Swiss researchers in the current issue of Biological Psychiatry.

18 May 2011

Scientists identify 'de novo' genetic mutations in autism spectrum disorder children

Scientists at the University of Washington (UW) Department of Genome Sciences have identified several sporadic or "de novo" genetic mutations in children with autism spectrum disorder. The researchers applied leading edge molecular biology techniques and massively parallel sequencing to simultaneously examine all of the protein coding portions of the genome, collectively called the exome.

17 May 2011

Otsuka Pharmaceutical reports OPC-34712 Phase 2 trial results in major depressive disorder

Otsuka Pharmaceutical Co., Ltd. (OPC) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) today announced results from a Phase 2 clinical trial of OPC-34712, a novel D2 dopamine partial agonist investigational product.

16 May 2011

Mylan introduces Risperidone Orally Disintegrating Tablets for schizophrenia treatment

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Risperidone Orally Disintegrating Tablets, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg, the generic version of Ortho-McNeil's Risperdal M-Tab, a treatment for schizophrenia.

13 May 2011

Two new research studies on schizophrenia

Two new research studies published in Biological Psychiatry point to progressive abnormalities in brain development that emerge as vulnerable individuals develop schizophrenia.

12 May 2011

Naurex announces completion of $18 million Series A financing

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced the completion of an $18 million Series A financing led by Adams Street Partners and Latterell Venture Partners.

11 May 2011

biocrea and Pfizer jointly presented details on novel PDE10 inhibitors

biocrea, a biopharmaceutical company focusing on novel treatments for disorders of the central nervous system (CNS), today reported details on the design and synthesis of novel, brain-penetrating phosphodiesterase-10 (PDE10) inhibitors developed in collaboration with Pfizer Inc. (NYSE: PFE). The data were featured in joint presentations1 with Pfizer at the recent 241st ACS National Meeting & Exposition, an event organized by the American Chemical Society (ACS).

10 May 2011

Elan Drug Technologies, Alkermes merge to form new company in Ireland

Alkermes, Inc. and Elan Corporation, plc today announced the execution of a definitive agreement under which Alkermes will merge with Elan Drug Technologies, the profitable, world-class drug formulation and manufacturing business unit of Elan, in a cash and stock transaction currently valued at approximately $960 million.

9 May 2011

Mithridion's MCD-386CR receives Orphan Drug designation from FDA for PSP treatment

Mithridion, Inc., a privately-owned clinical stage drug development company focusing on serious Central Nervous System disorders, announces that the U.S. Food and Drug Administration has awarded Orphan Drug designation for MCD-386CR, its lead drug candidate, for the treatment of Progressive Supranuclear Palsy.

9 May 2011

Summit Entertainment, Participant Media create depression awareness campaign

Inspired by Participant Media and Summit Entertainment's THE BEAVER, Participant has created a Social public Action Campaign to increase awareness about depression, teaming with three leading non-profit organizations known for effectively providing hope and help to those affected by depression and other forms of mental illness: the National Alliance on Mental Illness, To Write Love on Her Arms (TWLOHA) and the Kristin Brooks Hope Center.

7 May 2011

Researchers use virtual computer model to understand schizophrenic brains

Computer networks that can't forget fast enough can show symptoms of a kind of virtual schizophrenia, giving researchers further clues to the inner workings of schizophrenic brains, researchers at The University of Texas at Austin and Yale University have found.

6 May 2011

Schizophrenia News and Research

Latest Schizophrenia News and Research

New findings from STELARA psoriasis clinical trial to be presented at 22nd World Congress of Dermatology

Brain areas responsible for motor behavior might represent therapeutic targets for bipolar disorder

Evotec, PsychoGenics partner to offer integrated CNS drug discovery solutions

Disaster-response planning raises challenges for mental health services, bioethicists say

Johns Hopkins bioethicists urge disaster preparedness for mentally impaired

Researchers uncover new details of unusual biological mechanism in brains of diverse species

Adjusting life goals can help family caregivers prevent depressive symptoms: Study

Generic drugs to rule the market in the near future: Experts

New interactive website for patients with schizophrenia

Study: MMN might predict risk of developing schizophrenia

Scientists identify 'de novo' genetic mutations in autism spectrum disorder children

Otsuka Pharmaceutical reports OPC-34712 Phase 2 trial results in major depressive disorder

Mylan introduces Risperidone Orally Disintegrating Tablets for schizophrenia treatment

Two new research studies on schizophrenia

Naurex announces completion of $18 million Series A financing

biocrea and Pfizer jointly presented details on novel PDE10 inhibitors

Elan Drug Technologies, Alkermes merge to form new company in Ireland

Mithridion's MCD-386CR receives Orphan Drug designation from FDA for PSP treatment

Summit Entertainment, Participant Media create depression awareness campaign

Researchers use virtual computer model to understand schizophrenic brains

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Schizophrenia News and Research

Latest Schizophrenia News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in